[Managing lamivudine resistance in liver transplantation for hepatitis B liver disease].
Samuel
Didier
D
Centre Hépatobiliaire, INSERM U 785, Université Paris-Sud, Assistance Publique-Hopitaux de Paris, 14 avenue Paul Vaillant Couturier, 94800 Villejuif, France. didier.samuel@pbr.aphp.fr
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000517:prevention & control / Q000601:surgery*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D019694:Hepatitis B, Chronic / Q000601:surgery; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation; D063065:Organophosphonates / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D055502:Secondary Prevention; D016896:Treatment Outcome
D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D007136:Immunoglobulins; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C053001:adefovir; D000225:Adenine; C045213:hepatitis B hyperimmune globulin